Loading clinical trials...
Loading clinical trials...
A Single-centre, Randomised, Double-blind, Placebo-controlled, 3-way Multiple Dose, Cross-over, "Proof-of-concept" Study to Assess the Efficacy of a Single PBF-680 Oral Administration to Attenuate Adenosine 5'-Monophosphate (AMP) Challenge-induced Airway Hyperresponsiveness in Mild-to-moderate Asthmatics
Conditions
Interventions
PBF-680 5 mg
PBF-680 20 mg
+1 more
Locations
2
Spain
Hospital de la Santa Creu i Sant Pau
Barcelona, Barcelona, Spain
Palobiofarma S.L. (molecule owner)
Mataró, Barcelona, Spain
Start Date
December 1, 2013
Primary Completion Date
July 1, 2014
Completion Date
July 1, 2014
Last Updated
March 8, 2016
NCT07486401
NCT02327897
NCT07219173
NCT04706988
NCT04639791
NCT06471257
Lead Sponsor
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions